Saturn V Capital Management LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Saturn V Capital Management LP reported 26 stock positions worth $264.6 million. Its top holding was Argenx SE - ADR (ARGX) at 10.4% of the portfolio, followed by Disc Medicine (IRON, 8.6%) and Crinetics Pharmaceuticals (CRNX, 8.1%). Compared with Q1 2024, it opened 8 new positions, sold out of 3, added to 10 and reduced 8. The biggest buy was a new position in Cargo Therapeutics (CRGX) and the biggest sale Crinetics Pharmaceuticals (CRNX, shares −27%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $264.6M (Q2 2024)
- SEC Filing
- 0001964437-24-000007 ↗ filed Aug 14, 2024
Holdings Value
Holdings 26 stocks · $264.6M
| ARGX Argenx SE - ADR | 10.43% | 64,196 | $27.6M | Reduce -2.1% |
| IRON Disc Medicine Inc. | 8.57% | 503,089 | $22.7M | Add +97.4% |
| CRNX Crinetics Pharmaceuticals Inc. | 8.12% | 479,681 | $21.5M | Reduce -27.3% |
| PCVX Vaxcyte Inc. | 6.15% | 215,680 | $16.3M | Add +16.5% |
| ASND Ascendis Pharma A/S | 5.83% | 113,224 | $15.4M | Add +9.5% |
| CYTK Cytokinetics Inc. | 5.57% | 272,036 | $14.7M | Add +3.2% |
| BMRN Biomarin Pharmaceutical Inc. | 5.56% | 178,589 | $14.7M | Add +49.8% |
| COGT Cogent Biosciences Inc. | 5.33% | 1,673,919 | $14.1M | Add +5.0% |
| CRGX Cargo Therapeutics Inc. | 5.32% | 856,849 | $14.1M | New |
| KALV Kalvista Pharmaceuticals Inc. | 5.02% | 1,128,478 | $13.3M | Reduce -21.7% |
| CELC Celcuity Inc. | 4.71% | 760,941 | $12.5M | New |
| MRUS Merus NV | 3.68% | 164,773 | $9.7M | Reduce -56.3% |
| SNDX Syndax Pharmaceuticals Inc. | 3.26% | 419,654 | $8.6M | Add +5.4% |
| ABVX Abivax SA-ADR | 3.14% | 627,760 | $8.3M | Add +0.8% |
| IRWD Ironwood Pharmaceuticals Inc. | 2.74% | 1,113,824 | $7.3M | Add +17.9% |
| FOLD Amicus Therapeutics Inc. | 2.67% | 713,536 | $7.1M | Reduce -20.6% |
| ANAB Anaptysbio Inc. | 2.36% | 249,609 | $6.3M | Reduce -57.4% |
| PHAT Phathom Pharmaceuticals Inc. | 2.31% | 593,306 | $6.1M | Add +18.4% |
| ITOS Iteos Therapeutics Inc. | 2.06% | 367,429 | $5.5M | Reduce -5.1% |
| INZY Inozyme Pharma Inc. | 1.92% | 1,140,310 | $5.1M | New |
| NMRA Neumora Therapeutics Inc. | 1.45% | 390,084 | $3.8M | New |
| ELVN Enliven Therapeutics Inc. | 1.34% | 152,178 | $3.6M | New |
| LBPH Longboard Pharmaceuticals Inc. | 0.73% | 71,442 | $1.9M | New |
| RAPP Rapport Therapeutics Inc. | 0.62% | 70,000 | $1.6M | New |
| MORF Morphic Holding Inc. | 0.61% | 47,660 | $1.6M | Reduce -44.3% |
| CTNM Contineum Therapeutics Inc. Class A | 0.48% | 72,831 | $1.3M | New |
Portfolio Sells Q1 2024 → Q2 2024
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -27.3% | 8.12% | −4.27 |
| MRUS Merus NV | Reduce -56.3% | 3.68% | −3.12 |
| ANAB Anaptysbio Inc. | Reduce -57.4% | 2.36% | −2.93 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -21.7% | 5.02% | −1.83 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.68 |
| FOLD Amicus Therapeutics Inc. | Reduce -20.6% | 2.67% | −1.57 |
| GERN Geron Corp. | Sold out | 0.00% | −1.49 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −1.18 |
| MORF Morphic Holding Inc. | Reduce -44.3% | 0.61% | −0.59 |
| ITOS Iteos Therapeutics Inc. | Reduce -5.1% | 2.06% | −0.06 |
| ARGX Argenx SE - ADR | Reduce -2.1% | 10.43% | +0.08 |
Portfolio Buys Q1 2024 → Q2 2024
| CRGX Cargo Therapeutics Inc. | New | 5.32% | +5.32 |
| CELC Celcuity Inc. | New | 4.71% | +4.71 |
| IRON Disc Medicine Inc. | Add +97.4% | 8.57% | +2.21 |
| INZY Inozyme Pharma Inc. | New | 1.92% | +1.92 |
| NMRA Neumora Therapeutics Inc. | New | 1.45% | +1.45 |
| BMRN Biomarin Pharmaceutical Inc. | Add +49.8% | 5.56% | +1.38 |
| ELVN Enliven Therapeutics Inc. | New | 1.34% | +1.34 |
| PCVX Vaxcyte Inc. | Add +16.5% | 6.15% | +1.08 |
| COGT Cogent Biosciences Inc. | Add +5.0% | 5.33% | +1.03 |
| LBPH Longboard Pharmaceuticals Inc. | New | 0.73% | +0.73 |
| RAPP Rapport Therapeutics Inc. | New | 0.62% | +0.62 |
| CTNM Contineum Therapeutics Inc. Class A | New | 0.48% | +0.48 |
| PHAT Phathom Pharmaceuticals Inc. | Add +18.4% | 2.31% | +0.18 |
| ASND Ascendis Pharma A/S | Add +9.5% | 5.83% | −0.43 |
| ABVX Abivax SA-ADR | Add +0.8% | 3.14% | −0.44 |
| SNDX Syndax Pharmaceuticals Inc. | Add +5.4% | 3.26% | −0.54 |
| IRWD Ironwood Pharmaceuticals Inc. | Add +17.9% | 2.74% | −0.56 |
| CYTK Cytokinetics Inc. | Add +3.2% | 5.57% | −1.84 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |